These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

146 related articles for article (PubMed ID: 1532904)

  • 1. Influence of tamoxifen, aminoglutethimide and goserelin on human plasma IGF-I levels in breast cancer patients.
    Lien EA; Johannessen DC; Aakvaag A; Lønning PE
    J Steroid Biochem Mol Biol; 1992 Mar; 41(3-8):541-3. PubMed ID: 1532904
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Endocrine and clinical aspects of new compounds for treatment of hormone-related cancer in gynecology.
    von Matthiessen H; Distler W
    Recent Results Cancer Res; 1990; 118():190-5. PubMed ID: 2146725
    [No Abstract]   [Full Text] [Related]  

  • 3. Combined endocrine effects of LHRH agonist (Zoladex) and tamoxifen (Nolvadex) therapy in premenopausal women with breast cancer.
    Robertson JF; Walker KJ; Nicholson RI; Blamey RW
    Br J Surg; 1989 Dec; 76(12):1262-5. PubMed ID: 2532556
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Response to endocrine manipulation and oestrogen receptor concentration in large operable primary breast cancer.
    Anderson ED; Forrest AP; Levack PA; Chetty U; Hawkins RA
    Br J Cancer; 1989 Aug; 60(2):223-6. PubMed ID: 2527549
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Aromatization inhibition alone or in combination with GnRH agonists for the treatment of premenopausal breast cancer patients.
    Dowsett M; Stein RC; Coombes RC
    J Steroid Biochem Mol Biol; 1992 Sep; 43(1-3):155-9. PubMed ID: 1388047
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Randomized trial of tamoxifen versus aminoglutethimide and versus combined tamoxifen and aminoglutethimide in advanced postmenopausal breast cancer.
    Alonso-Muñoz MC; Ojeda-González MB; Beltran-Fabregat M; Dorca-Ribugent J; López-López L; Borrás-Balada J; Cardenal-Alemany F; Gómez-Batiste X; Fabregat-Mayol J; Viladiu-Quemada P
    Oncology; 1988; 45(5):350-3. PubMed ID: 3045726
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Influence of tamoxifen on plasma levels of insulin-like growth factor I and insulin-like growth factor binding protein I in breast cancer patients.
    Lønning PE; Hall K; Aakvaag A; Lien EA
    Cancer Res; 1992 Sep; 52(17):4719-23. PubMed ID: 1380889
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Arthralgia induced by endocrine treatment for breast cancer: A prospective study of serum levels of insulin like growth factor-I, its binding protein and oestrogens.
    Lintermans A; Vanderschueren D; Verhaeghe J; Van Asten K; Jans I; Van Herck E; Laenen A; Paridaens R; Billen J; Pauwels S; Vermeersch P; Wildiers H; Christiaens MR; Neven P
    Eur J Cancer; 2014 Nov; 50(17):2925-31. PubMed ID: 25304297
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Aminoglutethimide in the treatment of premenopausal patients with metastatic breast cancer.
    Wander HE; Blossey HC; Nagel GA
    Eur J Cancer Clin Oncol; 1986 Nov; 22(11):1371-4. PubMed ID: 3830219
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cross-over comparison of tamoxifen and aminoglutethimide in advanced breast cancer.
    Harvey HA; Lipton A; White DS; Santen RJ; Boucher AE; Shafik AS; Dixon RJ
    Cancer Res; 1982 Aug; 42(8 Suppl):3451s-3453s. PubMed ID: 6177405
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Treatment of advanced breast cancer with aminoglutethimide--response after previous tamoxifen treatment.
    Bezwoda WR; Derman DP; Browde S; Goss G; Lange M
    S Afr Med J; 1984 Sep; 66(10):372-4. PubMed ID: 6484759
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Plasma insulin-like growth factor I and its binding proteins 1 and 3 in postmenopausal patients with breast cancer receiving long term tamoxifen.
    Lahti EI; Knip M; Laatikainen TJ
    Cancer; 1994 Jul; 74(2):618-24. PubMed ID: 7518340
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The clinical and endocrine effects of 4-hydroxyandrostenedione alone and in combination with goserelin in premenopausal women with advanced breast cancer.
    Stein RC; Dowsett M; Hedley A; Gazet JC; Ford HT; Coombes RC
    Br J Cancer; 1990 Oct; 62(4):679-83. PubMed ID: 2145964
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The effect of endocrine therapy with medroxyprogesterone acetate, 4-hydroxyandrostenedione or tamoxifen on plasma concentrations of insulin-like growth factor (IGF)-I, IGF-II and IGFBP-1 in women with advanced breast cancer.
    Reed MJ; Christodoulides A; Koistinen R; Seppälä M; Teale JD; Ghilchik MW
    Int J Cancer; 1992 Sep; 52(2):208-12. PubMed ID: 1381703
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Suppression of serum insulin-like growth factor-1 levels in breast cancer patients during adjuvant tamoxifen therapy.
    Friedl A; Jordan VC; Pollak M
    Eur J Cancer; 1993; 29A(10):1368-72. PubMed ID: 8398260
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Complete estrogen blockade for the treatment of metastatic and early stage breast cancer.
    Michaud LB; Buzdar AU
    Drugs Aging; 2000 Apr; 16(4):261-71. PubMed ID: 10874521
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Sequential tamoxifen and aminoglutethimide versus tamoxifen alone in the adjuvant treatment of postmenopausal breast cancer patients: results of an Italian cooperative study.
    Boccardo F; Rubagotti A; Amoroso D; Mesiti M; Romeo D; Caroti C; Farris A; Cruciani G; Villa E; Schieppati G; Mustacchi G;
    J Clin Oncol; 2001 Nov; 19(22):4209-15. PubMed ID: 11709564
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A clinical trial of aminoglutethimide in advanced postmenopausal breast carcinoma: low response in patients previously treated with medroxyprogesterone.
    Alberto P; Mermillod B; Kaplan E; Goldhirsch A; Obrecht JP; Jungi F; Martz G; Barrelet L; Cavalli F
    Eur J Cancer Clin Oncol; 1985 Apr; 21(4):423-8. PubMed ID: 3891359
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Zoladex: endocrine and therapeutic effects in post-menopausal breast cancer.
    Harris AL; Carmichael J; Cantwell BM; Dowsett M
    Br J Cancer; 1989 Jan; 59(1):97-9. PubMed ID: 2527049
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Randomized trial of aminoglutethimide versus tamoxifen in metastatic breast cancer.
    Lipton A; Harvey HA; Santen RJ; Boucher A; White D; Bernath A; Dixon R; Richards G; Shafik A
    Cancer Res; 1982 Aug; 42(8 Suppl):3434s-3436s. PubMed ID: 7044526
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.